Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas
The goal of this program is to ensure that members of the interprofessional oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with relapsed/refractory B-cell lymphomas.
This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other health care professionals who care for patients with relapsed/refractory B-cell lymphomas.
Upon completion of this activity, participants should be able to:
- Describe the standard of care and the rationale for the development of novel treatment options for relapsed/refractory B-cell lymphomas.
- Discuss the mechanism of action and evidence from clinical trials supporting the use of novel small molecule inhibitors in the management of patients with relapsed/refractory B-cell lymphomas.
- Identify the special considerations associated with the use of currently approved small molecule inhibitors to develop an individualized treatment plan for patients with relapsed/refractory B-cell lymphomas.
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: 0836-0000-18-122-L01-P
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation